{
    "clinical_study": {
        "@rank": "43523", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Other", 
                "description": "Period 1: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Other", 
                "description": "Period 1: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state"
            }
        ], 
        "brief_summary": {
            "textblock": "1. Objective: To evaluate the pharmacokinetic profiles of an SR 75 mg tramadol/650 mg\n           acetaminophen formulation compared with an immediate release (IR) 37.5 mg tramadol/325\n           mg acetaminophen formulation after a single dose and at steady state\n\n        2. Subjects: Healthy subject\n\n        3. Methods: A phase I study to evaluate the pharmacokinetic sustained release and\n           immediate release treatment profiles at steady state."
        }, 
        "brief_title": "Assessment of the Pharmacokinetics of a Sustained Release Formulation of a Tramadol/Acetaminophen Combination", 
        "completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "condition": "Pain", 
        "detailed_description": {
            "textblock": "This study was open, randomized, 2-period, 2-treatment multiple-dose crossover study of\n      immediate release treatment and sustained release treatment was designed to assess the\n      pharmacokinetics after a 2-day repeated administration in which the steady state was\n      achieved."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects between the ages of 20 and 45 years\n\n          -  Subjects weighed \u2265 45 kg and were within 20% of their ideal body weight\n\n          -  No clinically relevant abnormalities identified by vital sign measurement, 12-lead\n             electrocardiography and routine laboratory test\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity or histories of sensitivity to either tramadol or acetaminophen\n\n          -  Evidence or histories of clinically significant renal, digestive, respiratory,\n             musculoskeletal, endocrine, psychiatric, neurological, hematological or\n             cardiovascular diseases\n\n          -  Taking any prescription or herbal medicines within 2 weeks before the study or any\n             over-the-counter medication within 1 week before the study\n\n          -  Systolic blood pressure (SBP) \u2265 160 mmHg or \u2264 100 mmHg or diastolic blood pressure\n             (DBP) \u2265 95 mmHg or \u2264 60 mmHg\n\n          -  Any surgical or medical conditions that could affect drug absorption"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01880125", 
            "org_study_id": "YJ4-101"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A", 
                "Group B"
            ], 
            "description": "Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.", 
            "intervention_name": "Tramadol HCI/Acetaminophen", 
            "intervention_type": "Drug", 
            "other_name": [
                "ULTRACET immediate release tablet", 
                "YJAT sustained release tablet"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Acetaminophen", 
                "Tramadol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Tramadol", 
            "Acetaminophen", 
            "Pharmacokinetics", 
            "Sustained release", 
            "Immediate release"
        ], 
        "lastchanged_date": "June 17, 2013", 
        "number_of_arms": "2", 
        "official_title": "Clinical Trial to Compare the Pharmacokinetics Profile of YJAT Sustained Release Tablet and ULTRACET\u00ae Immediate Release Tablet After Oral Administration to Healthy Male Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Korea: Food and Drug Administration", 
                "Korea: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Bio-equivalence of Cmax and AUC at steady state of tramadol and acetaminophen", 
            "measure": "Evaluate the pharmacokinetic profiles of tramadol and acetaminophen at steady state", 
            "safety_issue": "No", 
            "time_frame": "0 to 36 hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01880125"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Tmax, Half-life, Accumulation index of tramadol and acetaminophen at steady state.\nCmax, AUC, Tmax, Half-life of O-desmethyltramadol at steady state", 
            "measure": "Evaluate the pharmacokinetics profiles of tramadol, acetaminophen and O-desmethyltramadol at steady state", 
            "safety_issue": "No", 
            "time_frame": "0 to 36 hour"
        }, 
        "source": "Yungjin Pharm. Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Chonbuk National University Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Yungjin Pharm. Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}